Potential conflicts of interest. J. M. P. received grants or contracts from the European Commission–European Federation of Pharmaceutical Industries Associations (IMI2 853966-2, IMI2 777377), European Commission (H2020 847989), and Instituto de Salud Carlos III (PI19/01898 and PI22/01770); consulting fees from Boehringer-Ingelheim, NovoNordisk, and MSD; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Intercept, NovoNordisk, and Gilead; and support for attending meetings and/or travel from NovoNordisk, Madrigal, and Rubio. V. C. received royalties from UpToDate. G. C. received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Basilea Pharmaceutica and Gilead Sciences and support for attending meetings and/or travel from Angelini Pharma, Pfizer, and MSD. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.